Sight Sciences uses minimally invasive or non-invasive approaches to target underlying causes of prevalent eye diseases and seeks to create more effective treatment paradigms that supplant conventional approaches. Strategic initiatives include OMNIEdge launch and positive reimbursement for TearCare, aiming to capture market share and expand the Surgical Glaucoma product line with enhanced provider training.
Cyborg Score Rationale
Full-year 2025 revenue declined approximately 3% to $77.3M-$77.4M. Cash position was approximately $92M at year-end 2025. The company shows revenue headwinds and unprofitability, but has expanded leadership team and positive clinical evidence supporting key products.
Top Insights
Q4 2025 revenue expected to be $20.3M–$20.4M (+7% YoY), though full-year 2025 declined ~3% YoY to $77.3M–$77.4M
Q4 Dry Eye revenue surged ~130% YoY to ~$0.7M, though full-year declined to $1.6M from $4.0M in 2024
New executive appointments (COO and CFO effective November 2025) signal focus on scaling reimbursed interventional dry eye and MIGS commercial efforts
Medicare expanded coverage for TearCare procedure (CPT code 0563T) and commercial insurers expanded coverage for minimally invasive glaucoma procedures including OMNI
Named Competitors
iStent/Hydrus/Cypass Systems — Competing implant-based MIGS devices
XEN Gel Stent — Alternative minimally invasive glaucoma surgery solution
(March 2026) Q4 and full-year 2025 earnings report scheduled for March 4, 2026 with preliminary results showing flat revenue and dry eye revenue decline
(November 2025) New COO and CFO appointed to support scaling of dry eye and glaucoma commercial efforts
(November 2025) Three peer-reviewed publications demonstrating OMNI surgical system effectiveness in lowering intraocular pressure and medication use
Open the full interactive Sight Sciences, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.